Plague is a severe and potentially life-threatening infectious disease caused by the bacterium Yersinia pestis. Our company offers comprehensive services in the development of plague vaccines and therapeutics. Leveraging cutting-edge technologies and a deep understanding of Yersinia pestis pathophysiology, we are dedicated to advancing the frontiers of plague prevention and therapeutics.
Overview of Plague
Plague, a notorious infectious disease caused by the bacterium Yersinia pestis, has been a scourge throughout human history, responsible for widespread pandemics that have reshaped the course of civilization. Characterized by its rapid progression and high mortality rate, plague poses a significant threat to public health, even in the modern era. The disease manifests in various forms, including bubonic, septicemic, and pneumonic plague, each presenting unique challenges for diagnosis and therapeutics.
Fig.1 Different routes of interhuman transmission and human infection from plague sources. (Barbieri R., et al., 2020)
Vaccine Development for Plague
Subunit Vaccines
Subunit vaccines have shown promise in preclinical studies. They focus on specific antigens, such as the F1 capsular protein and the LcrV protein, which are crucial for Yersinia pestis virulence.
Live Attenuated Vaccines
Live attenuated vaccines use weakened forms of Yersinia pestis that can stimulate an immune response similar to that of natural infection. These vaccines have the potential to provide long-lasting immunity.
DNA Vaccines
DNA vaccines represent a modern approach to vaccine development. They involve the use of plasmids containing genes encoding for Yersinia pestis antigens.
Vectored Vaccines
Vectored vaccines use other viruses or bacteria to deliver Yersinia pestis antigens. This approach can elicit a strong immune response by leveraging the potent delivery mechanisms of the vector organism.
Therapeutics Development for Plague
Antibiotic Therapeutics
Antibiotics remain the cornerstone of plague therapeutics. Traditional agents such as streptomycin and gentamicin are commonly used. However, the emergence of antibiotic-resistant strains has spurred the search for new antimicrobials with unique mechanisms of action.
Host-Directed Therapies
Host-directed therapies aim to modulate the host's response to infection, rather than targeting the pathogen directly. This approach can involve the use of immunomodulatory agents or interventions that enhance the host's natural defenses against Yersinia pestis.
Our Services
The development of effective plague vaccines and therapies is a complex and ongoing scientific endeavor. As we continue to unravel the intricacies of Y. pestis biology and pathogenesis, we are better equipped to devise strategies that can offer protection and therapies. Our company stands at the forefront of this fight and is committed to delivering innovative solutions.
Preclinical Research
- Drug Safety Evaluation
- In Vivo Pharmacokinetics Study
- In Vitro Pharmacokinetics Study
- Activity Testing
- Drug Resistance Evaluation
Disease Models
- African Green Monkey (AGM) Models
- Mouse Models: pgm(-) strains
- Brown Norway strain of Rattus norvegicus
- Cynomolgus Macaque Models
- African Green Monkey Models
- Caenorhabditis elegans (Nematode) Models
- Flea Models (Xenopsylla cheopis)
Complementing our vaccine and therapy development efforts, we offer comprehensive plague preclinical research services to support the advancement of plague-related drug research and therapy development. If you are interested in our services, please feel free to contact us.
References
- Barbieri, R., et al. "Yersinia pestis: the natural history of plague." Clinical microbiology reviews 34.1 (2020): 10-1128.
- Sun, Wei, and Amit K. Singh. "Plague vaccine: recent progress and prospects." npj Vaccines 4.1 (2019): 11.
- Yang, Ruifu. "Plague: recognition, treatment, and prevention." Journal of clinical microbiology 56.1 (2018): 10-1128.
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
